VX-670

RNA / oligonucleotide

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Myotonic Dystrophy Type 1
Phase 1/2 (1)
Myotonic Dystrophy Type 1

Competitive landscape

This drug's own stage for Myotonic Dystrophy Type 1: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
VX-670: this drugPhase 2RNA / oligonucleotideDMPK CUG-repeat RNAnot yet gradedNo reviewed efficacy summary in this indication
Delpacibart EtedesiranPhase 3RNA / oligonucleotideDMPKnot yet gradedNo reviewed efficacy summary in this indication
Pitolisant (Wakix)Phase 2Small moleculeHistamine H3 receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SAR446268Phase 1/2Gene therapy / editingDMPKnot yet gradedNo reviewed efficacy summary in this indication
SRP-1003
Phase 1/2(overall)
RNA / oligonucleotideDMPK (dystrophia myotonica protein kinase)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow VX-670 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Phase 1/2Myotonic Dystrophy Type 1Active not recruiting
Est. primary completion 2027-02-02 · NCT06185764 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 2Myotonic Dystrophy Type 1Enrolling by invitation
Est. primary completion 2029-01-30 · NCT06926621 · CT.gov ↗
What to watch

See the full readout calendar ↗